Notice :
Impact of Recent Change Health Care National Outage. Learn More
Notice :
Impact of Recent Change Health Care National Outage. Learn More

Clinical Trial

Trial Protocol ID USOR 23212_JS004-008-III-SCLC

Trial Description

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Mohit Narang, M.D.

Disease Types

Sponsors

  • Parexel
  • Shanghai Junshi Biosciences Co., Ltd.

ClinicalTrials.gov NCT ID

  • NCT06095583